Decrease of intra-ocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction
Prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
Treatment of patients with neovascular (wet) age-related macular degeneration (AMD). Treatment of adult patients with visual impairment due to diabetic macular oedema (DME) . The treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (RVO). The treatment of visual impaiment due to choroidal neovascularization (CNV) . Lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.The treatment of proliferative diabetic retinopathy (PDR)
Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells
Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD)
Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction